Skip to main content
ASAM 2024 State of the Art Course Main banner
Final Program


Final Program
Back
Q & A

Initiation & Discontinuation

Physician-Delegated Unobserved Induction with Buprenorphine in Pharmacies

Thursday, October 17, 2024
9:50 AM – 10:10 AM ET
Location: Grand Ballroom I-V, Level 3

    Presenter(s)

  • Traci C. Green, PhD, MSc

    Professor
    Brandeis University, Heller School for Social Policy and Management The Warren Alpert School of Medicine of Brown University Brown University School of Public Health
    Brandeis University/Brown University, Massachusetts

    Slides
Most Americans live within 5 miles of a pharmacy, and pharmacists are highly skilled healthcare professionals who provide counseling and dispense life-saving medication—including buprenorphine and methadone--to patients on a daily basis. Pharmacists can administer injectable medications and can be trained to more actively support patients with substance use disorder. Nearly every state has the capacity to provide pharmacist collaborative care models or to adopt pharmacist-led models as a component of much needed expansions of the behavioral health workforce. This session will review key legal and policy structures surrounding pharmacy-based care, present results and implications from a trial of unobserved induction with buprenorphine in pharmacies, and consider prospects for delivery models of pharmacy-based methadone for opioid use disorder in community pharmacies.

Learning Objectives:

Learners will be able to:
  • Describe the importance of using computational methods to classify phenotypes of patients with opioid use disorder in emergency departments and outline the basic approaches for applying these techniques.